Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

Authors: Simon Bowman, Robert I. Fox, Thomas Dörner, Xavier Mariette, Athena Papas, Thomas Grader‐Beck, Benjamin A. Fisher, Filipe Barcelos, Salvatore De Vita, Hendrik Schulze‐Koops, Robert J. Moots, G. Junge, J. Woznicki, Monika Sopala, Wen‐Lin Luo, Wolfgang Hueber - The Lancet 2021 cited by 215